New Therapy via ARTG-Registered* Nasal Spray in Sydney for Eligible DVA Patients
Exploring innovative approaches to mental wellness, our clinics also offer a new treatment option for DVA patients seeking relief from persistent emotional challenges. This therapy, utilising an ARTG- registered* nasal spray under ongoing medical supervision in Sydney, helps support mood regulation.
The intranasal program begins with an initial online screening form completed by each DVA patient. This is followed by a telehealth appointment with a nurse practitioner and a comprehensive psychiatric assessment.
What is the cost?
The cost of treatment for eligible patients may be covered by the DVA on a case-by-case basis. Our team will discuss details with you.
Cancellation fees apply for appointments canceled with less than 24 hours notice.
What is the treatment process?
Treatment is in Sydney involves a structured schedule over three months, with ongoing support based on individual clinical response to treatment:
Month One (Induction Phase): 8 sessions
Month Two (Maintenance Phase): 4 sessions
Month Three (Ongoing Phase): 2 to 4 sessions, determined by response to treatment and personalised care plan, with continued support thereafter.
Induction Month (Week 1-4):
Month 1 - Induction - 8 sessions - 2/week
Maintenance Month (Week 5-8):
Month 2 - Maintenance- 4 sessions - 1/week
Ongoing Treatment (Week 9 and Beyond):
Month 3 onwards - 1 session per week or 1 per fortnight depending on individual response to treatment.
*ARTG ID 311827
What is psychedelic-assisted therapy?
Separate from the intranasal treatment for patients suffering from persistent low mood, GoodMind also provides psychedelic-assisted therapy for eligible patients. This is a type of treatment that involves psychotherapy alongside the administration of a psychedelic compound that is prescribed by an authorised psychiatrist in an appropriate medical setting.
The goal of psychedelic-assisted therapy is to help address emotional obstacles and long-term problems expediently by utilizing the psychedelic journey, rather than spending months or years in talk therapy slowly working through them. The psychological support element of the therapy is facilitated by multidisciplinary care teams, including clinical psychologists and psychotherapists.
However, only certain psychiatrists, registered under Australian law and given regulatory authorisation, will be able to prescribe the psychedelic medicines.
These psychiatrists will also need permission from a human research ethics committee that ensures the treatment protocol is appropriate for the patient and the required safety measures are in place.
Patients won’t be able to use the medicine without the supervision of their psychiatrist, nor will they be able to take the medicine with them.
Preparatory session
Building mutual trust with the psychotherapist, establishing processes of practical and interpersonal support in preparation for the dosing session
Dosing session
An authorized psychiatrist administers a measured dose of the psychedelic substance in a strictly controlled medical setting to the patient with an eligible mental health condition.
Integration session
In subsequent integration sessions, patients are facilitated by the therapists to explore and interpret the contents of their psychedelic-assisted experiences. This may include identifying insights or interpreting ideas or sensations that arose during the psychedelic session.